简介:摘要:本文通过综合分析我国大数据与人工智能技术的发展态势,探讨了其对经济、社会和科技领域的深远影响。首先,我们对我国大数据和人工智能技术的基本概念进行了阐述,并回顾了其发展历程。其次,我们介绍了我国大数据与人工智能技术在各个领域的应用与研究现状,包括金融、医疗、交通等。然后,我们分析了我国大数据与人工智能技术发展的优势和挑战,并提出了一些促进其发展的政策建议。最后,我们展望了未来我国大数据与人工智能技术的发展趋势,认为我国将进一步加强研究与创新,推动人工智能与大数据的融合应用,并促进其在产业升级和社会进步中发挥更重要的作用。本文的研究对于了解我国大数据与人工智能技术发展的态势,把握其对经济和社会的影响具有重要的参考价值。
简介: 【摘要】 目的:研究慢性阻塞性肺疾病急性加重期合并肺栓塞应用低分子肝素钙的价值。方法:以 2017年 5月 -2019年 7月笔者所在医院接诊的慢性阻塞性肺疾病急性加重期合并肺栓塞病患 60例为研究对象,将之采用电脑随机双盲法分成试验组( n=30)和对照组( n=30)。对所有入选者都施以基础对症治疗,同时对试验组加用低分子肝素钙,对对照组加用肝素钠注射液。分析两组不良反应的发生情况,比较临床疗效等指标。结果:试验组不良反应发生率为 3.33%,低于对照组的 16.67%,差异有统计学意义( P<0.05)。试验组治疗后 FEV1水平为( 2.65±0.68) L、 FEV1/FVC水平为( 64.23±10.05) %,均优于对照组的( 1.97±0.52) L、( 56.14±9.28) %,差异均有统计学意义( P<0.05)。试验组治疗总有效率为 93.33%,高于对照组的 66.67%,差异有统计学意义( P<0.05)。结论:利用低分子肝素钙对慢性阻塞性肺疾病急性加重期合并肺栓塞病患进行佐治,可显著提升其临床疗效,促进肺功能改善,减少不良反应发生风险,建议采纳。 【关键词】 慢性阻塞性肺疾病急性加重期 ; 低分子肝素钙 ; 肺栓塞 ; 临床疗效 [Abstract] Objective: To study the value of low molecular weight heparin calcium in patients with acute exacerbation of COPD and pulmonary embolism. Methods: from May 2017 to July 2019, 60 patients with acute exacerbation of chronic obstructive pulmonary disease (COPD) and pulmonary embolism (PE) received by our hospital were divided into two groups: experimental group (n = 30) and control group (n = 30). All the selected patients were treated with basic symptomatic treatment. At the same time, low molecular weight heparin calcium was added to the experimental group and heparin sodium injection was added to the control group. The occurrence of adverse reactions in the two groups was analyzed and the clinical efficacy was compared. Results: the incidence of adverse reactions in the experimental group was 3.33%, which was lower than that in the control group (16.67%) (P < 0.05). The level of FEV1 and FEV1 / FVC in the experimental group were (2.65 ± 0.68) l and (64.23 ± 10.05)%, which were superior to those in the control group (1.97 ± 0.52) l and (56.14 ± 9.28)%, respectively (P < 0.05). The total effective rate of the experimental group was 93.33%, higher than 66.67% of the control group, the difference was statistically significant (P < 0.05). Conclusion: low molecular weight heparin calcium can significantly improve the clinical effect, promote the improvement of pulmonary function and reduce the risk of adverse reactions.
简介: 【摘要】 目的 研究分析前列地尔联合辛伐他汀治疗慢性阻塞性肺疾病( COPD)合并肺源性心脏病的(肺心病)近期疗效。方法 此次研究的对象是选择 60例 COPD同时合并肺心病急性加重期患者,将其临床资料进行回顾性分析,并按入院先后顺序分为对照组、前列地尔治疗组和联合治疗组, 每组 20例。比较三组治疗前后氧分压( PO2)及二氧化碳分压( PCO2)等动脉血气分析结果、肺动脉收缩压变化及运动耐量变化情况。结果 三组治疗均有效, 治疗前后比较差异有统计学意义( P<0.05), 治疗后患者的缺氧及二氧化碳潴留改善程度、肺动脉收缩压降低幅度及运动耐量增加程度的比较中, 前列地尔治疗组优于对照组( P<0.01), 联合治疗组优于前列地尔组( P<0.05)。结论 前列地尔联合辛伐他汀治疗 COPD合并肺心病近期疗效显著, 值得推广。 【关键词】 前列地尔;辛伐他汀;慢性阻塞性肺疾病;慢性肺源性心脏病 [Abstract] Objective To study the short-term effect of alprostadil combined with simvastatin in the treatment of chronic obstructive pulmonary disease (COPD) with pulmonary heart disease (cor pulmonale). Methods 60 patients with COPD and acute exacerbation of cor pulmonale were selected in this study. The clinical data were analyzed retrospectively. The patients were divided into control group, alprostadil group and combined treatment group according to the order of admission, 20 cases in each group. The arterial blood gas analysis results of PO2 and PCO2, the changes of pulmonary systolic pressure and exercise tolerance were compared before and after treatment. Results the three groups were effective, and the difference was statistically significant (P<0.05). After treatment, the improvement of the degree of hypoxia and carbon dioxide retention, the reduction of pulmonary artery systolic pressure and the increase of exercise tolerance * were better than those of the control group (P<0.01). The combined treatment group was superior to the alprostadil group (P<0.05). Conclusion alprostadil combined with simvastatin has a significant short-term effect on COPD with cor pulmonale, which is worth popularizing.
简介:摘要前瞻性纳入2017年12月至2018年9月河北医科大学第三医院经临床及MRI确诊,并接受经皮椎间孔镜下髓核摘除术(PTED)治疗的19例腰椎间盘单侧侧后方突出患者,于术前1 d,术后3、30、90 d行腰5(L5)、骶1(S1)神经根扩散张量成像(DTI)。由2名放射科医师于L5、S1患侧神经近、中、远节段及同节段健侧相应部位以"播点"法勾画感兴趣区(ROI ),测量DTI参数各向异性分数(FA)和表观扩散系数(ADC)值,计算每侧神经3个ROI的平均值。采用配对t检验比较患侧与健侧神经DTI参数的差异,手术前后DTI参数的比较采用单因素方差分析或Kruskal-Wallis H检验。结果显示:(1)术前1 d L5神经患侧和健侧FA值分别为0.35±0.03、0.45±0.01, S1患侧和健侧分别为0.36±0.02、0.46±0.02,L5、S1患侧神经根FA值低于健侧(t=-10.188、-37.683,P均<0.001);L5患侧ADC值为(1.65±0.13)×10-3 mm2/s、健侧(1.39±0.12)×10-3 mm2/s,S1患侧(1.63±0.05)×10-3 mm2/s、健侧(1.44± 0.08)×10-3 mm2/s,患侧高于健侧,差异有统计学意义(t=8.527、11.832,P均<0.001)。(2)从术前1 d至术后90 d,患侧L5、S1神经FA值逐渐升高,ADC值逐渐减低。术后90 d L5、S1患侧和健侧神经根DTI参数比较差异无统计学意义(P均>0.05)。表明DTI可用于定量评估腰骶神经PTED术后修复状况。